| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
REVIEW |
Department of Hematology and Oncology, Emory School of Medicine, Winship Cancer Institute, 1365 Clifton Road, NE, Atlanta, Georgia 30322, USA
(Requests for offprints should be addressed to K S Kimbro; Email: sean.kimbro{at}emoryhealthcare.org)
The tumor microenvironment is best characterized as a fluctuation of hypoxia and nutrient deprivation, which leads to epigenetic and genetic adaptation of clones and increased invasiveness and metastasis. In turn, these hypoxic adaptations make the tumors more difficult to treat and confer increased resistance to current therapies. Part of this adaptation is the regulation of gene products in response to hypoxia. Many of these hypoxia-regulated genes are mediated by the hypoxia-inducible factor 1 (HIF-1) complex, which is composed of a heterodimer pair of HIF-1
and HIF-1ß. This heterodimer binds to the promoter of hypoxia-responsive genes, while interacting with other transcription factors, such as p300, signal and transducer of transcription 3, and Redox effector factor 1/apurinic/apyrimidinic endonuclease. HIF-1 levels itself can be regulated by hypoxia transcriptionally and post-translationally through ubiquitination; but the magnitude of the response is modulated by several other pathways, including free radicals that affect crosstalk with HIF-1/HIF-1ß transcriptional activities. HIF-1 has emerged as an important transcription factor in breast cancer and prostate cancer biology, and is expressed in the early stages of mammary and prostate carcinogenesis. Its expression is correlated with diagnostic and prognostic indicators for early relapse and metastatic disease, thus making HIF-1 a potential prognostic biomarker in proteomic assessments of breast and prostate cancers. The importance of HIF-1 in tumor progression makes it a logical target for chemoprevention strategies in patients at higher genetic risk of breast and prostate cancer with Cox 2 inhibitors or 2-methoxyestradiol, as well as a target for new approaches to inhibiting angiogenesis. The crosstalk between estrogen signaling pathways and HIF-1 is still not fully defined in breast cancer, but downstream estrogen receptor signaling may be a candidate for estrogen modulation of HIF-1 levels. In prostate cancer, androgens upregulate HIF-1 through androgen-regulated autocrine receptor tyrosine kinase receptor signaling. This review will put into perspective the role of HIF-1 in endocrine oncology and present new data on HIF-1 signaling and the potential for targeted therapies, including combinatory hormonal therapies.
This article has been cited by other articles:
|
|
 |
|
  A. Thangasamy, J. Rogge, and S. Ammanamanchi Recepteur d'Origine Nantais Tyrosine Kinase Is a Direct Target of Hypoxia-inducible Factor-1{alpha}-mediated Invasion of Breast Carcinoma Cells J. Biol. Chem., May 22, 2009; 284(21): 14001 - 14010. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Bianchini, M. Loiarro, P. Bielli, R. Busa, M. P. Paronetto, F. Loreni, R. Geremia, and C. Sette Phosphorylation of eIF4E by MNKs supports protein synthesis, cell cycle progression and proliferation in prostate cancer cells Carcinogenesis, December 1, 2008; 29(12): 2279 - 2288. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kato, A. Sadarangani, S. Lange, A. M. Delpiano, M. Vargas, J. Branes, J. Carvajal, S. Lipkowitz, G. I. Owen, and M. A. Cuello 2-Methoxyestradiol Mediates Apoptosis Through Caspase-Dependent and Independent Mechanisms in Ovarian Cancer Cells But Not in Normal Counterparts Reproductive Sciences, November 1, 2008; 15(9): 878 - 894. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Kunigal, S. S. Lakka, P. Joseph, N. Estes, and J. S. Rao Matrix metalloproteinase-9 Inhibition Down-Regulates Radiation-Induced Nuclear Factor-{kappa}B Activity Leading to Apoptosis in Breast Tumors Clin. Cancer Res., June 1, 2008; 14(11): 3617 - 3626. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J. Jacobs, A. W. Hsing, E. B. Bain, V. L. Stevens, Y. Wang, J. Chen, S. J. Chanock, S. L. Zheng, J. Xu, M. J. Thun, et al. Polymorphisms in Angiogenesis-Related Genes and Prostate Cancer Cancer Epidemiol. Biomarkers Prev., April 1, 2008; 17(4): 972 - 977. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Rudolfsson and A. Bergh Testosterone-stimulated growth of the rat prostate may be driven by tissue hypoxia and hypoxia-inducible factor-1{alpha} J. Endocrinol., January 1, 2008; 196(1): 11 - 19. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
